Page last updated: 2024-12-07
xylidyl blue i
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
xylidyl blue I: RN from Chem Abstracts Index Guide 1984; RN not in Chemline 5/84 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 135442960 |
SCHEMBL ID | 2861735 |
MeSH ID | M0121485 |
Synonyms (22)
Synonym |
---|
xylidyl blue i |
einecs 239-012-8 |
14936-97-1 |
1-azo-2-hydroxy-3-(2,4-dimethylcarboxyanilido)naphthalene-1'-(2-hydroxybenzene-5-sulfonic acid) sodium salt |
2-[2-hydroxy-3-(2,4-xylylcarbamoyl)-1-naphthylazo]-1-phenol-4-sulfonic acid sodium salt |
sodium 3-((3-(((2,4-dimethylphenyl)amino)carbonyl)-2-hydroxy-1-naphthyl)azo)-4-hydroxybenzenesulphonate |
magonsulfonate |
FT-0637162 |
SCHEMBL2861735 |
AKOS024285054 |
xylidyl blue i sodium salt |
J-610035 |
mfcd00003890 |
xb-i; magonsulfonate |
sodium (e)-3-((3-(2,4-dimethylphenylcarbamoyl)-2-hydroxynaphthalen-1-yl)diazenyl)-4-hydroxybenzenesulfonate |
T70316 |
xylylazo violet i [spectrophotometric reagent for mg] |
sodium3-(2-(3-((2,4-dimethylphenyl)carbamoyl)-2-oxonaphthalen-1(2h)-ylidene)hydrazineyl)-4-hydroxybenzenesulfonate |
2321383-50-8 |
sodium 3-(2-(3-((2,4-dimethylphenyl)carbamoyl)-2-oxonaphthalen-1(2h)-ylidene)hydrazineyl)-4-hydroxybenzenesulfonate |
sodium;3-[[3-[(2,4-dimethylphenyl)carbamoyl]-2-hydroxynaphthalen-1-yl]diazenyl]-4-hydroxybenzenesulfonate |
SODIUM (E)-3-((3-((2,4-DIMETHYLPHENYL)CARBAMOYL)-2-HYDROXYNAPHTHALEN-1-YL)DIAZENYL)-4-HYDROXYBENZENESULFONATE |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |